Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo NVCMOPF +3.33%82 5-Year Yield-on-Cost % is 3.14 as of Jul. 16, 2026, which is 103% above its 10-year median of 1.55. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $54.43 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 515 Drug Manufacturers companies, Cosmo NV ranks better than 56.7% on this metric.
Cosmo NV's yield on cost for the quarter that ended in Dec. 2025 was 3.14.
The historical rank and industry rank for Cosmo NV's 5-Year Yield-on-Cost % or its related term are showing as below:
CMOPF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.84 Med: 1.55 Max: 4.03
Current: 3.14
During the past 13 years, Cosmo NV's highest Yield on Cost was 4.03. The lowest was 0.84. And the median was 1.55.
CMOPF's 5-Year Yield-on-Cost % is ranked better than 56.7% of 515
companies
in the Drug Manufacturers industry
Industry Median: 2.25
vs CMOPF: 3.14
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Cosmo NV 5-Year Yield-on-Cost % Related Terms
CMOPF vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Cosmo NV's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Cosmo NV is calculated as
Cosmo NV (CMOPF) has a 5-Year Yield-on-Cost % of 3.14 as of Jul. 16, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cosmo NV and its competitors. This is 103% above median its historical median of 1.55. Over the past decade, Cosmo NV's 5-Year Yield-on-Cost % has ranged from 0.84 to 4.03. According to the industry distribution chart, Cosmo NV ranks #223 out of 515 companies in the Drug Manufacturers industry, placing it in the top 43.3%.
Is Cosmo NV's 5-Year Yield-on-Cost % too high?
Cosmo NV's current 5-Year Yield-on-Cost % of 3.14 is 103% above median its 10-year median of 1.55. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 4.03. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.25. Cosmo NV's value of 3.14 is 39.6% above this industry median. Based on the distribution chart, Cosmo NV ranks #223 out of 515 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #223 out of 515 companies for 5-Year Yield-on-Cost %. This puts Cosmo NV in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.25. Cosmo NV's value of 3.14 is 39.6% above this benchmark. Historically, Cosmo NV's own 5-Year Yield-on-Cost % has ranged from 0.84 to 4.03 over the past decade. While the company's 10-year median is 1.55 vs. the industry median of 2.25, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.25, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current 5-Year Yield-on-Cost % of 3.14 is 39.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current 5-Year Yield-on-Cost % is 3.14, which is 103% above median its own 10-year median of 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.43, compared to a current price of $78.79 — trading 44.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 3.14, which is 103% above median its 10-year median of 1.55 and 39.6% above the Drug Manufacturers industry median of 2.25. Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current 5-Year Yield-on-Cost % is 3.14 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $78.79 is trading 44.8% above its estimated GF Value™ of $54.43.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
5-Year Yield-on-Cost %: 3.14 (103% above median its 10-year median of 1.55)
GF Value™: $54.43 vs. price of $78.79 (44.8% above fair value)
Industry Position: 39.6% above the Drug Manufacturers median (#223 of 515)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score
Get the complete analysis for CMOPF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
